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Abstract 
In a program to identify new structural entities for the inhibition of the HIV-1 reverse transcriptase 
(RT) enzyme via database searching, a series of RT pharmacophores were developed. By utilising a 
novel filtering technique, the National Cancer Institute database of compounds was scanned producing 
15 compounds to be screened for activity. A notable inclusion was a series of gossypol derivatives. The 
testing of a series of compounds revealed the parent compound gossypol to be an HIV-1 reverse 
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transcriptase inhibitor. These results suggest that at least part of its anti-HIV activity is due to gossypol 
targeting the non-nucleoside inhibitor binding pocket of RT. 
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Introduction 
The use of ligand-based computer-aided molecular modelling techniques to investigate the non-
nucleoside inhibitor binding pocket (NNIBP) of the reverse transcriptase (RT) enzyme has been 
documented. The breadth of coverage encompasses QSAR methodologies,1,2,3 molecular field-based 
similarity studies,4,5 neural networks6 and pharmacophore generation.6 Each study maintains its identity 
whether it be by limiting its training set to a single class of inhibitors,6 or by comparing two different 
ligand-based approaches3 to name just two. 
 
The RT enzyme presents an interesting target for computer-aided modelling studies as the NNIBP is 
known to be flexible, moving both to accommodate inhibitors, and to take on different shapes 
depending on the inhibitor bound.7 This must be considered in any pharmacophore-based approach as a 
rigid pocket geometry is usually assumed for this computational aspect. Thus, pharmacophore models 
generated for the NNIBP are usually limited to a single class of compound. While these models could 
be used for database searching and subsequent docking experiments to reveal new structural entities as 
possible inhibitors, they do limit the potential versatility of the technique by simply ignoring one of the 
vital and significant features of the site, i.e. the pocket flexibility. We have developed our 
pharmacophore models to incorporate the possibility of pocket flexibility by the implementation of a 
novel filtering system during database searching. Therefore, the aim was not to produce the traditional 
‘common’ pharmacophores derived from a range of different structural classes of inhibitors, but rather 
to produce a range of pharmacophores corresponding to each inhibitor class.  
Essentially, we are not using ‘pharmacophores‘ in the traditional sense, i.e. trying to produce a 
quantitative pharmacophore that precisely defines a space occupied by a congeneric set of ligands. We 
feel that this has been done already for HIV-RT. The purpose of our study was to generate 
pharmacophores, not to be used for predictions, but rather to try and search a different molecular space 
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in database searching, and therefore give rise to a different set of hits for testing. Our approach here 
was to not eliminate possibilities (e.g. by using a “shape” option within the pharmacophore software), 
but rather, to use separately generated pharmacophores, defined for each inhibitor class, as filters. 
Therefore, the end result would be a series of molecules (hits) which should fit all potential pocket 
shapes, as currently reported. This procedure would take into account not only ligand 
flexibility/adaptability, but enzyme flexibility because it does not try and define one (quantitative) 
pharmacophore for a series of different pocket shapes – rather, it would try to find molecules that will 
fit all pocket shapes. Furthermore, this methodology would unearth compounds that can be ‘induced’ to 
fit several pharmacophore models through conformational changes, or by different fittings within the 
model. This is an additional advantage of this method, as examples have already been reported 
whereby different derivatives of the same lead compound bind in a different orientation within the 
NNIBP. Therefore, by allowing these alternative positions, we are starting to take into account a degree 
of enzyme flexibility as it is currently defined in the literature. Furthermore, the pharmacophore 
software incorporates the different mappings (binding modes) for each molecule and will therefore also 
take into account possible enzyme flexibility. 
 
This technique was adopted in an attempt to find new structural entities as potential NNIBP inhibitors 
by searching different spaces within compound databases. 
 
Methodology 
The automated pharmacophore development program Catalyst8,9 was used to generate separate 
pharmacophore models, using default parameters, for a series of four distinct NNI classes: nevirapine, 
hydroxyethoxymethylphenylthiothymine (HEPT), tetrahydroimidazobenzodiazepinone (TIBO), and α-
anilinophenylacetamide (APA) as well as an additional ‘combined model’. These pharmacophores 
were used as a filter by sequentially running them through the NCI database. This approach did not aim 
to refine all the data into generating one hypothesis, but to keep the hypotheses separated into 
compound classes. These multiple hypotheses were then used to search what is probably a more diverse 
structural space within the database. This could possibly, at least indirectly, take into account that the 
NNIBP is flexible and changes shape with different structural entities. The compounds provided by the 
NCI were tested for their HIV-1 reverse transcriptase inhibition. 
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Results and Discussion 
Pharmacophore Generation 
Catalyst generated the pharmacophore models for the four distinct NNI classes: nevirapine, HEPT, 
TIBO, and APA and the additional ‘combined model’, essentially by determining common features 
(such as H-bond acceptors, hydrophobic regions, etc) and correlating their location in space to the 
activity of a series (training set) of inhibitor compounds. The actual hypotheses scores were calculated 
according to the number of bits required to completely describe a hypothesis. Simpler hypotheses 
require fewer bits for a complete description, and the assumption is made that simpler hypotheses are 
better. 
 
The entire program was developed for use on rigid pocket systems, a constraint that the RT enzyme 
does not satisfy. It does, however, model ligand flexibility by considering the conformations of each 
inhibitor used in the training set within a set energy range. Further, ligand based drug design programs 
assume that the inhibitors used within the training set interact with the active site in the same manner. 
The NNIs to be analysed may orientate themselves slightly differently upon binding and interact with 
slightly different amino acid sets within the active site. This is suggested by the structural diversity 
shown by the inhibitors and the fact that different NNRTIs do not necessarily show cross resistance to 
one another.10 For this reason, Catalyst was allowed to generate hypotheses for each of the reverse 
transcriptase inhibitor (RTI) classes in turn, allowing for the assumption that within each class, all 
inhibitors will bind in the same fashion. 
 
Catalyst limits the choice of different features to a maximum of five (a feature can be used more than 
once in a pharmacophore). We chose the following features: hydrophobic aliphatic, aromatic π-
stacking, hydrogen bond donor and hydrogen bond acceptor.  
 
Separate pharmacophores were generated for a series of nevirapine, TIBO, HEPT, and APA analogues, 
and a further ‘combined hypothesis’ was also generated. The compounds used in the training sets and 
their activities11,12,13 are listed in Tables 1-4. 
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Entry R R2 IC50 (nM)
1 CH3 H 80
2 CH2OH H 3000 
3 CH2OEt H 1300 
4 CH2OPh H 120 
5 CH2OCH2Ph H 270 
6 CH2O(CH2)2Ph H 420 
7 CH2NHPh H 60 
8 CH2SPh H 1030 
9 CH2O(Ph-o-Me) H 290 
10 CH2O(Ph-m-Me) H 2430 
11 CH2O(Ph-p-Me) H 580 
12 CH2O(Ph-o-OH) H 460 
13 CH2O(Ph-o-Cl) H 3050 
14 CH2O(Ph-p-NH2) H 100
15 CH2O(Ph-p-NHEt) H 80
16 CH2O(Ph-p-OMe) H 1040 
17 CH2O(Ph-p-CN) H 410 
18 CH2O(Ph-p-NO2) H 1130
19 CH2Ph H 140 
20 CH2OCH2Ph OMe 920 
21 CHO OMe 240 
22 CH2OH OMe 50 
23 CH2OPh OMe 4000 
24 CH2Ph OH 340 
25 CH2OCH2Ph OH 110 
26 CH2OH OH 420 













Entry R X Z
IC50 
(nM) 
1 DMAa 9-Cl S 34 
2 DMA 8-Cl S 4.3 
3 DMA 8-F S 5.8 
4 DMA 8-SMe S 5 
5 DMA 8-OMe S 33.9 
6 DMA 8-OEt S 95.9 
7 DMA 8-CN S 56.3 
8 DMA 8-CHO S 188 
9 DMA 8-CONH2 O 6360
10 DMA 8-Br O 47.3 
11 DMA 8-I O 88 
12 DMA 8-I S 47.4 
13 DMA 8-C≡CH O 437.6 
14 DMA 8-C≡CH S 29.6 
15 DMA 8-Et O >5940 
16 DMA 8-Me O 989 
17 DMA 8-Me S 13.6 
18 DMA 10-OMe O 6630 
19 DMA 10-OMe S 4725 
20 DMA 9,10-diCl S 25.5 
21 DMA 10-Br S 1075 
22 DMA H S 44 
23 DMA 8-Br S 3 
24 propyl O >500000
a DMA = dimethylallyl 
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Entry X R R2 R3
IC50 
(nM)
1 O Me H CH2OH 6500 
2 O Me H Me 330 
3 O Me H Ph 93 
4 O C2H5 H CH2OH 120








H CH2OH 59 
8 O Et H Me 22 
9 O Et H Ph 4.9 


















































1 NO2 H (+) 1731 
2 NO2 H (–) 33 
3 COMe H (+) 6506 
4 COMe H (–) 19 
5 COMe Me (+) 2109 
6 COMe Me (–) 5 
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Nevirapine Pharmacophores 
Initial attempts at producing pharmacophores based upon the nevirapine series of inhibitors produced a 
correlation coefficient ‘r’ (actual vs predicted activity) of 0.40. It has been reported that the lack of 
correlation between actual and predicted RT inhibitory activities might have been due to the 4-
substituted nevirapine analogues interacting in a different manner with the pocket than the 2,4-
disubstituted derivatives.14 Consequently, separate pharmacophores were generated for the 4-
substituted and the 2,4-disubstituted nevirapine analogues. This resulted in a strong increase in the 
correlation between the actual and predicted activities, with the hypothesis for the 2,4-disubstituted 
compounds improving from 0.40 to 0.82. The 4-substituted analogues also show a slight improvement 
with the correlation increasing from 0.40 to 0.55. Both these hypotheses are illustrated in Figure 1 (A
and B).
















Table 1, entry 14  
Figure 1: The highest scoring hypotheses generated for the 2,4-disubstituted nevirapine training set 
(A) and the 4-substituted nevirapine training set (B). Sample compounds overlaid on each 
pharmacophore are entry 25 and entry 14 respectively (see table 1). C shows the highest scoring 
catalyst hypotheses for the 4-substituted and 2,4-disubstituted nevirapine analogues overlaid. The mesh 
spheres illustrate the location constraints of each feature and are colour coded: Hydrogen Bond Donor 
= magenta, with the proposed positioning of the H-bond shown by an arrow or cone pointing to the 
proposed position of the interacting group on the protein (larger sphere); Hydrogen Bond Acceptor = 
green, likewise with the proposed position of the H-Bond illustrated; Hydrophobic Aliphatic regions = 
blue; Hydrophobic Aromatic region = orange with proposed π-stacking interaction shown by an arrow 
and the plane of the aromatic ring of the ligand constrained by a blue grid. Note in these hypotheses, 
the hydrophilic region (right) with common hydrogen bond donor features and the hydrophobic region 
(left) with common π-stacking regions.  
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This result confirms that the compounds possessing a 2-substituent bind in a different orientation to 
those compounds that lack the 2-substituent. It is possible that the dipyridodiazepinone ring system 
rotates to access the enzymatic residues near the position of the 2-substituent. This rotation would 
almost certainly lead to a change in the binding environment of the 4-position. 
 
In an attempt to further characterise the different binding orientations of the 4-substituted nevirapine 
compounds compared with the 2,4-disubstituted analogues, their respective hypotheses were overlaid 
(Figure 1C). Both hypotheses share a common aromatic region (orange) and a common hydrogen bond 
donor region (magenta). Differences in binding include a hydrogen bond acceptor region (green) that is 
present for the 4-substituted derivatives, whereas the 2,4-disubstituted derivatives seem to favour 
another hydrophobic interaction (blue). A further notable feature of these hypotheses is the separation 
of hydrophobic and hydrophilic regions. 
 
TIBO, HEPT and APA Pharmacophores 
Further pharmacophores generated were based upon TIBO, HEPT and APA inhibitors and their 
derivatives. Figure 2 illustrates the highest scoring hypotheses for each, together with an example 
inhibitor overlaid. Tables 2, 3 and 4 list the compounds used in the training sets.12,13 
























Table 4, entry 3  
Figure 2: The highest scoring hypotheses for TIBO (A), HEPT (B) and APA (C) and derivatives. 
Overlaid on each are example inhibitors (entries 2, 3 and 3 from Tables 2, 3, and 4 respectively). 
Colour coding of pharmacophore features is as described for Figure 1. 
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The training set of TIBO derivatives has inhibitory values spanning 5 orders of magnitude, ranging 
from 4 nM to 500,000 nM. It is highly recommended for training sets in Catalyst pharmacophores to 
span 5 orders of magnitude. The pharmacophore itself (Fig 2A) consists of one aromatic π-stacking 
interaction (orange), which maps to the single phenyl ring present in all TIBO derivatives, two 
hydrophobic groups (blue) which correspond approximately to the 8-membered ring and to the 
dimethylallyl (DMA) substituent, and one hydrogen bond acceptor region (green) which overlays 
precisely with the sulfur substituent attached to the 5-membered ring system. The hypothesis has a 
correlation of 0.84, with most of the significant deviation observed for predicted IC50 values greater 
than 500 nM. 
 
The hypothesis generated for the HEPT derivatives (Fig 2B) consists of one aromatic region (orange), 
two hydrophobic regions (blue) and one hydrogen bond acceptor (green). Analysis of the hypothesis 
mapped reveals that significant interaction occurs around the central uracil ring with the hydrogen bond 
acceptor region located on the O atom on one side, and on the opposite side, a hydrophobic region 
which maps to the alkyl substituent. Of the two phenyl groups at the extremities of the molecule, one 
has a π-stacking interaction with the receptor and the other a hydrophobic (aliphatic) interaction. The 
hypothesis estimates the activities of the training set well, giving a correlation of 0.95. 
 
APA is the last of the non-nucleoside inhibitors where the binding location has been determined via a 
crystal structure. Only six compounds were included in the training set. This was the result of the 
limited amount of published literature available on APA derivatives, as well as difficulties in relating 
the absolute configuration of the stereogenic carbons present to reported activities. For this reason the 
hypothesis must be regarded with a degree of caution if it was to be used to predict activity. 
Nevertheless, it predicts (see Figure 2C) that the most important interactions for APA-RT inhibitors 
will be two aromatic π-stacking interactions mapping onto the two phenyl rings of the molecules, one 
hydrophobic centre, which maps to the ortho substituent on the di-substituted ring, and one electron 
donating (hydrogen bond acceptor) interaction which overlays with the amide oxygen atom. The 
correlation coefficient for the APA series is 0.999, and this is likely a result of the structurally 
congeneric training set used. 
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The Combined Non-Nucleoside Inhibitor Pharmacophore Model 
The four non-nucleoside inhibitor classes analysed so far have all been shown by X-ray crystallography 
to share a common binding location, the NNIBP.15 Structure based drug design has found that all of 
these inhibitors seem to adopt a similar general conformation when bound to the pocket of RT.16 It has 
also been speculated that the interactions between the inhibitors and the enzyme are similar for all four 
of the NNIs analysed, but not necessarily identical. If this is so, then analysis of the similarities of the 
pharmacophore models produced should show that at least some of the interactions identified in each 
hypothesis model are common to all, and in a similar spatial location. It is not envisaged that all 
interactions will be in precisely the same location, due to the flexibility of the NNIBP. For example, the 
inhibitors are all shown, or proposed, to be interacting with Tyr 188, but it is extremely unlikely that 
Tyr 188, and indeed any of the other pocket residues, will occupy exactly the same spatial location in 
every case. 
 
To investigate this idea, a further pharmacophore model was generated by combining all of the 
inhibitors used previously into a single training set. This model was used as a basis for determining the 
common features and general locations of important interactions within the pocket. 
 
The combined hypothesis (Fig 3A) identifies two hydrophobic interactions, one of which is speculated 
to be involved in π-stacking interactions with the receptor, the other to be a hydrophobic aliphatic 
interaction. The other type of interaction believed important is a hydrogen bond acceptor. 
(A) (B) (C) 
Figure 3: A: The combined hypothesis for the NNIs. The molecule used to illustrate the hypothesis is 
Entry 3 in Table 4 (see Fig. 2(C) for structure). B: The HEPT hypothesis overlaid with the combined 
model hypothesis showing a good likeness. C: APA and TIBO hypotheses overlaid showing a good 
likeness, typical of any two of the models overlaid. Common to all of the hypotheses produced so far, 
seems to be the location of hydrophobic (features coloured blue and orange) and hydrophilic 
interactions (features coloured green and magenta), at opposite ends of the pharmacophores. Colour 
coding of features is as described in Figure 1. 
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As was the case with the nevirapine derivatives, it is likely that the low correlation observed occurs as a 
result of some of the inhibitors interacting with the NNIBP in a subtly different way. 
In order to test the validity of the combined model, it was overlaid with each of the original 
pharmacophores to determine the extent of the similarities between the individual structural models and 
the combined hypothesis. In a typical example, Figure 3B shows the HEPT model overlaid with the 
combined model and illustrates the general similarities. Further, when the individual pharmacophore 
models were overlaid with each other, it further exemplified the similarities that existed with the 
pharmacophores. As one example, Figure 3C shows the hypotheses generated for the APA and TIBO 
series overlaid, a result typical for all cases when two of these NNI pharmacophores were 
superimposed. The aromatic regions overlay in approximately the same location, suggesting that the π-
stacking between ligand and receptor occurs in the same fashion irrespective of the ligand. Slight 
deviations in the positions of the aromatic rings could also be accounted for by the three different π-
stacking interactions that can occur; parallel displaced, perpendicular and parallel tilted, as well as by 
the flexibility of the pocket. 
Figure 3C also shows the hydrogen bond acceptor and hydrophobic regions located in similar spatial 
positions. Again this seems to be a fairly general result, as any two of the hypotheses overlaid always 
shared at least one hydrogen bond acceptor (green) or hydrophobic region (blue), along with the 
aromatic π-stacking (orange).  
As stated before, it is not expected that different classes of inhibitors will interact with the NNIBP in 
precisely the same manner. This would be unreasonable, due to the structural diversity present in the 
inhibitors and the known flexibility of the pocket. Thus, small differences in the locations of important 
features are tolerable, as we are primarily concerned with determining the approximate location of 
these ‘overlapping’ interactions. The fact that there is such variation between the inhibitors suggests 
that provided that the locations of their binding features are positioned in approximately the correct 
location, the NNIBP will accommodate structurally different molecules leading to individual induced 
fit mechanisms in the RT enzyme based on the specific nature of the ligand. 
 
Database Filtering 
The combined NNI hypothesis was used to search the NCI database.17 This initial examination yielded 
47,028 hits. In an attempt to refine the number of NCI search hits down to something more 
manageable, it was decided to filter the NCI database hits by using all of the pharmacophores generated 
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successively, resulting in an end product that would only contain compounds that fitted all hypotheses. 
This, in theory, should produce compounds that possess all of the essential features necessary for 
potent RT inhibitory activity. 
Table 5 shows how the number of database search hits was progressively reduced as each 
pharmacophore model was passed through the reduced database – providing the same hypotheses are 
used, the order with which the database is filtered is irrelevant as the same outcome will result. After 
utilising all of the pharmacophores for NNIs of known binding site as a series of filters, 540 
compounds remained which satisfied all of the constraints on the spatial location of features imposed 
by the models. In an attempt to further refine the database results into a manageable number, manual 
filtering was employed, using the following criteria: 
• Compounds lacking hydrophilic character were excluded from further analysis, since it has been 
speculated that certain hydrophilic interactions play a significant role in ‘navigating’ the substrate 
into the pocket. 
• Compounds possessing bulky, or unusually long side chains were omitted from the analysis. This 
was a result of Catalyst mapping compounds to the selected pharmacophores, which were in reality 
far too large to fit into the NNIBP. Excluded volume restraints were not utilised in this study. 
• Molecules with no conformational potential for adopting anything of a ‘butterfly’ conformation 
were also removed from further selection. 
• Structural novelty 
Table 5: Database filtering using the different pharmacophore hypotheses. Note, the order with which 
the (same) hypotheses are used is irrelevant to the final outcome. 








Nevirapine 4-substituted 540 
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Analysis of Selected Structural Elements from Database Searching and the RT Inhibitory Action of 
Gossypol 
In support of the quality of the filters used, two hydrophobic regions were always present in these 
compounds, presenting an array of conformations, emulating known non-nucleoside inhibitors of HIV-
1 reverse transcriptase, and their well established hydrophobic interactions. Further support for the 
usefulness of the pharmacophores were the presence of numerous ADAM (alkenyldiarylmethane) type 

















2 3  
Figure 4: An example of an ADAM (arenediarylmethane) structure (2), which emerged as a hit from 
our database searching. Also illustrated is an example of a known ADAM (3) with its activity as a 
reverse transcriptase inhibitor. 
 
A series of gossypol analogues comprising of long alkyl chain derivatives also emerged as hits from 
our database searches. Since our pharmacophore models contained no volume constraints, and these 
long chain hydrophobic imine functionalities did not overlay on any of the features contained within 
the hypotheses generated, it was not considered necessary to synthesize these molecules, instead the 
parent compound (1) was used for testing. Figure 5 also shows gossypol overlaid on the ‘combined’ 
pharmacophores hypothesis. An important aspect to note is the observation that sections from both 
halves of the dimeric gossypol map onto the pharmacophores, suggesting that the basic monomeric unit 










Figure 5: Structure of the parent compound gossypol (1) and gossypol overlaid on the combined 
hypothesis.  
14
The presence of gossypol derivatives in the database search results posed an interesting question. The 
parent gossypol compound was reported in 1989 as an anti-HIV agent,19 however, it was stated that it 
was unlikely to be primarily a reverse transcriptase inhibitor, although no data was presented for the 
effects of gossypol in a reverse transcriptase assay. In a later article (1995),20 the effects of gossylic 
iminolactone (GIL) were compared to those of AZT to ascertain whether they have different targets. 
From the outset, this publication never considered the possibility that gossypol might act at a different 
site on the reverse transcriptase enzyme (e.g. the non-nucleoside inhibitor binding pocket) when 
compared to AZT (a known nucleoside inhibitor). This paper concludes that GIL does not inhibit RT, 
but also suggests that gossypol derivatives may exert their antiviral effects in a different manner to the 
parent compound (1) due to repeated observations that the two sets of compounds exhibit markedly 
different chemical and biological properties. 
 
Considering that the base structure of this compound arose as a hit from our database searching, and 
that there has been no data published showing the inhibitory effects (or otherwise) of gossypol on the 
reverse transcriptase enzyme, we included the structure (1) in our testing for anti-RT activity.  
 
Biological Testing 
A series of sixteen compounds arising from our pharmacophore studies, including 15 donated by the 
NCI (see Fig 6) and racemic gossypol, were tested for their anti-RT activity using nevirapine and 
foscarnet as positive controls and unphosphorylated AZT as a negative control. The only structure to 
emerge as possessing activity was gossypol (Fig. 7). At the highest concentration tested (100mg/mL), it 
inhibited reverse transcriptase by greater than 99% of its normal activity. This inhibition is dose 
dependant: at the lower concentrations of 20 and 4 µg/mL, it restricted RT activity to 73.2% and 76.3% 
of normal activity respectively, but at a concentration of 0.8 µg/mL, had lost its inhibitory effects. 
These results suggest that gossypol is, in part, a reverse transcriptase inhibitor. Certainly, the anti-HIV 
activity of gossypol cannot be attributed solely to its RT inhibition – indeed notable compounds have 
been shown to have multiple modes of action, including the michellamine class of compounds that are 
also reverse transcriptase inhibitors, but are known to act at two additional sites to account for their 
anti-HIV activity.21 The results from our study conclusively demonstrate that gossypol is a weak 
reverse transcriptase inhibitor, and strongly suggest that the site of this action is the non-nucleoside 


























































































































































Figure 7: In vitro inhibition of HIV-1 reverse transcriptase by gossypol. Nevirapine and foscarent are 
used as the positive controls while unphosphorylated AZT is used as the negative control. 
 
Conclusions 
A series of pharmacophores were developed for the NNIBP of the RT enzyme of HIV-1. These 
pharmacophore hypotheses were designed for database searching in such a fashion as to incorporate 
some consideration of the known flexibility of this pocket. A search of the NCI database resulted in a 
number of hits, a selection of which were tested for their RT inhibition activity. Emerging from these 
results was gossypol, already reported as an anti-HIV agent, however earlier reported as unlikely to be 
acting on the RT enzyme. Our testing revealed gossypol to be an RT inhibitor of significance, and that 




Gossypol was purchased from Sigma-Aldrich and was tested as the racemic mixture of atropisomers 
without further purification. All other compounds were generously supplied by the National Cancer 
Institute and tested as supplied. 
 
Biological Assay 
The mechanism of action of gossypol at the level of HIV-RT was determined in an in vitro assay using 
solubilised HIV as the source of the enzyme. Nevirapine and foscarnet were included as positive 
(active against RT) controls. Unphosphorylated AZT was included as a negative control. The RT 
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inhibition reaction was performed in a 96 well U-bottomed microtitre plate (Nunc). Equal volumes of 
solubilised virus and the test or control compound dilutions were mixed and incubated at room 
temperature for 15 minutes before being added in duplicate to wells containing reaction mix (reaction 
mix contains 50mM Tris HCl pH 7.8, 10mM MgCl2, 5mM dithiothreitol, 10 units poly(rA).poly(dT)10, 
2 mg/mL dATP, 5mCi 3HTTP). 
 
After 3 hours incubation at 37oC, the DNA product was precipitated by addition of trichloroacetic acid. 
Precipitated products were collected and washed using a cell-harvester (Filtermate 196). After addition 
of liquid scintillant (40 microscint), counts per minute (cpm) were determined on a Top Count 
Microplate Scintillant Counter. The average cpm for each drug dilution was obtained and compared to 
the virus only (no drug) control. A dose-response curve (% RT inhibition vs drug concentration) was 
then plotted for each drug. 
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